Inactive Instrument

Neuropathix, Inc.

Equities

NPTX

US64132Q1094

Biotechnology & Medical Research

Kannalife, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020

August 12, 2020 at 03:39 pm EDT

Kannalife, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced total revenue - ar was USD 0 compared to USD 52,768 a year ago. Operating loss was USD 1.489 million compared to USD 554,772 a year ago. Net loss was USD 2.058 million compared to USD 782,075 a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.01 a year ago. For the half year, total revenue - ar was USD 0 compared to USD 102,059 a year ago. Operating loss was USD 1.873 million compared to USD 1.057 million a year ago. Net loss was USD 2.366 million compared to USD 1.628 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago.

Latest news about Neuropathix, Inc.

Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Neuropathix, Inc. announced that it has received $0.15 million in funding	22-03-20	CI
Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board	21-08-12	CI
Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-06	CI
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-30	CI
Neuropathix, Inc. announced that it has received $1.2075 million in funding from Lyons Capital, LLC	21-02-09	CI
Neuropathix, Inc. Appoints Daniel Richman to Board of Advisors	21-01-12	CI
Neuropathix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI
Kannalife, Inc. has Changed its Name to Neuropathix, Inc	20-11-06	CI
Kannalife, Inc. has Changed its Name to Neuropathix, Inc	20-11-05	CI
Kannalife, Inc. Appoints Tage Honoré as the Chairman of the Company’s Board of Advisors	20-09-17	CI
Kannalife, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-12	CI
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories	20-07-09	CI
Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors	20-06-02	CI
Kannalife, Inc. announced that it expects to receive $0.156 million in funding	20-06-01	CI
Kannalife, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-14	CI
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD	20-04-14	CI
Kannalife, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-30	CI
Kannalife, Inc. announced that it expects to receive $0.2 million in funding	20-03-11	CI
Kannalife, Inc. Strengthens Intellectual Property Portfolio with New Chinese-Issued Patent	20-02-20	CI
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN	20-02-11	CI

Chart Neuropathix, Inc.

Duration

Period

More charts

Company Profile

Neuropathix, Inc. is a biopharmaceutical company. It is focused on discovering, developing, and commercializing novel therapeutics from its proprietary synthetic cannabinoid derivative platform that are potentially useful for a range of inflammatory and neuropathic pain-related diseases. Its product candidates include KLS-13019 and KLS-13023. KLS-13019 can control mechanical sensitivity and inflammation associated with chemotherapy-induced peripheral neuropathy (CIPN) in the absence of tolerance development and also reduce opioid craving behavior. KLS-13023 is a drug candidate that includes synthetic cannabidiol (CBD) formulated in a gel capsule designed for potential use in humans. Its drug discovery platform potentially treats neurological and oxidative stress-related disorders, such as overt hepatic encephalopathy (OHE), chronic traumatic encephalopathy (CTE), and CIPN, with current good manufacturing practices (cGMP) pharmaceutical grade semi-synthetic and synthetic cannabinoids.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.29B
ARGENX SE	+2.13%	22.18B
BIONTECH SE	-15.84%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-14.65%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.97B
SAREPTA THERAPEUTICS, INC.	+31.35%	12.17B

Bio Therapeutic Drugs